炎症性腸疾患治療薬市場：タイプ別、薬剤クラス別、投与経路別、流通チャネル別-2025-2030年世界予測

炎症性腸疾患治療薬市場は、2023年に202億6,000万米ドルと評価され、2024年には212億米ドルに達すると予測され、CAGR 4.81％で成長し、2030年には281億6,000万米ドルに達すると予測されています。

炎症性腸疾患（IBD）治療には、クローン病や潰瘍性大腸炎などの慢性疾患の炎症や症状を管理するための治療法が含まれます。効果的なIBD治療が必要とされる背景には、これらの疾患の世界の罹患率の増加があり、その結果、患者の罹患率は大きくなっています。用途は、生物製剤、低分子製剤、バイオシミラー、新興の遺伝子治療薬などの医薬品に及び、主に疾患の寛解の達成と維持を目的としています。最終用途の範囲は、病院、診療所、在宅医療に及ぶ。主な成長促進要因としては、創薬の進歩、生物製剤ポートフォリオの拡大、個別化医療アプローチの継続的研究が挙げられます。さらに、より良い疾病管理と患者のアドヒアランスのためにデジタルヘルスツールを統合する動向も高まっています。最新のビジネスチャンスのひとつは、介入を調整するための有望な領域であるマイクロバイオームを標的とした治療の開発です。さらに、費用対効果とアクセスの向上により、バイオシミラーが普及する可能性もあります。しかし、市場は厳しい規制のハードル、研究開発費の高騰、ブランド薬の収入源に影響を与える特許切れなどの課題に直面しています。支払者や保険会社はコスト抑制の圧力をかけ、収益性に影響を与える競合価格戦略をとっています。イノベーションは、精密医療と人工知能を活用した創薬に重点を置いた共同作業を通じて、最も花開く可能性があります。腸脳軸の調査によって新たな治療の道が開ける可能性がある一方、患者中心の研究によってより効果的に治療を調整できるかもしれないです。市場は高度な競合と統合を示し、戦略的提携やパートナーシップを必要とします。全体として、この市場は、科学的イノベーションと進化するヘルスケアの優先順位に後押しされたダイナミックな市場であるが、その可能性を十分に発揮するには、規制面や経済面での大きな課題を克服する必要があります。

市場力学：急速に進化する炎症性腸疾患治療薬市場の主要市場インサイトを公開

炎症性腸疾患治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の炎症性腸疾患の有病率の増加
  • IBD治療に対する啓発プログラムの増加
• 市場抑制要因
  • IBD治療の高額な治療費
• 市場機会
  • 新規IBD治療薬開発のための研究開発活動の活発化
  • IBD治療に関連する新規治療薬の承認の増加
• 市場の課題
  • 炎症性腸疾患治療薬に関する規制上のハードルと長い承認プロセス

ポーターのファイブフォース：炎症性腸疾患治療薬市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：炎症性腸疾患治療薬市場における外部からの影響の把握

外部マクロ環境要因は、炎症性腸疾患治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析炎症性腸疾患治療薬市場における競合情勢の把握

炎症性腸疾患治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス炎症性腸疾患治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、炎症性腸疾患治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨炎症性腸疾患治療薬市場における成功への道筋を描く

炎症性腸疾患治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で炎症性腸疾患の罹患率が増加
    • IBD治療に関する啓発活動の促進
  • 抑制要因
    • IBD治療の高額な治療費
  • 機会
    • 新たなIBD治療の開発に向けた研究開発活動の活発化
    • IBD治療に関連する新規治療薬の承認増加
  • 課題
    • 炎症性腸疾患治療における規制上のハードルと長期にわたる承認プロセス
• 市場セグメンテーション分析
  • タイプ：クローン病の罹患率増加に対応するための炎症性腸疾患治療薬の使用増加
  • 流通チャネル：利便性により、オンライン薬局を通じたIBD薬の入手性が高まっている
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 炎症性腸疾患治療薬市場：タイプ別

• クローン病
• 潰瘍性大腸炎

第7章 炎症性腸疾患治療薬市場薬剤クラス別

• アミノサリチル酸
• 抗インテグリン
• コルチコステロイド
• IL阻害剤
• JAK阻害剤
• TNF阻害剤

第8章 炎症性腸疾患治療薬市場：投与経路別

• 注射可能
• オーラル

第9章 炎症性腸疾患治療薬市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第10章 南北アメリカの炎症性腸疾患治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の炎症性腸疾患治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの炎症性腸疾患治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • FDAが潰瘍性大腸炎治療薬スカイリージを承認、アッヴィのIBD治療選択肢が拡大
  • アッヴィとフューチャージェンが協力し、炎症性腸疾患の先進的治療法を開発
  • サノフィとテバが協力し、炎症性腸疾患の新しい治療を開発
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Abivax
• Bristol-Myers Squibb Company
• Cipla Limited
• Eli Lilly and Company
• Entera Bio Ltd.
• GlaxoSmithKline PLC
• Ironwood Pharmaceuticals, Inc.
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Morphic Therapeutic, Inc.
• Nestle S.A.
• OPKO Health, Inc.
• Pfizer Inc.
• Sanofi SA
• Sun Pharma Limited
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• UCB S.A.
• Viatris Inc.
• Zealand Pharma A/S

LIST OF FIGURES

• FIGURE 1. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY AMINOSALICYLATES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ANTI-INTEGRIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY IL INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 37. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 39. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 40. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 44. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 58. AUSTRALIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 59. CHINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 60. CHINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 61. CHINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 62. CHINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 63. INDIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. INDIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 65. INDIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 66. INDIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 70. INDONESIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 74. JAPAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 78. MALAYSIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 82. PHILIPPINES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 86. SINGAPORE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH KOREA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 94. TAIWAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 98. THAILAND INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 102. VIETNAM INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 111. DENMARK INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 115. EGYPT INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 119. FINLAND INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 123. FRANCE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 127. GERMANY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 131. ISRAEL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 132. ITALY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 133. ITALY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 134. ITALY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 135. ITALY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 139. NETHERLANDS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 143. NIGERIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 147. NORWAY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 148. POLAND INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 149. POLAND INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 150. POLAND INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 151. POLAND INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 152. QATAR INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 153. QATAR INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 154. QATAR INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 155. QATAR INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 159. RUSSIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 163. SAUDI ARABIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 171. SPAIN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 175. SWEDEN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 179. SWITZERLAND INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 183. TURKEY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 187. UNITED ARAB EMIRATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 191. UNITED KINGDOM INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 192. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 193. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

The Inflammatory Bowel Disease Treatment Market was valued at USD 20.26 billion in 2023, expected to reach USD 21.20 billion in 2024, and is projected to grow at a CAGR of 4.81%, to USD 28.16 billion by 2030.

Inflammatory Bowel Disease (IBD) treatment encompasses therapies designed to manage the inflammation and symptoms of chronic disorders like Crohn's disease and ulcerative colitis. The necessity for effective IBD treatments is driven by the increasing global incidence of these diseases, which result in significant patient morbidity. Applications span pharmaceuticals including biologics, small molecules, biosimilars, and emerging gene therapies, aimed primarily at achieving and maintaining disease remission. The end-use scope extends to hospitals, clinics, and home care settings. Key growth drivers include advances in drug discovery, an expanding biologics portfolio, and ongoing research into personalized medicine approaches. Furthermore, there is a growing trend toward integrating digital health tools for better disease management and patient adherence. One of the latest opportunities is developing treatments targeting the microbiome, a promising domain for tailoring interventions. Additionally, there's potential for biosimilars to gain traction due to cost-effectiveness and increased access. However, the market faces challenges such as stringent regulatory hurdles, high R&D costs, and patent expiries affecting revenue streams for branded drugs. Payers and insurers exert pressure to control costs, leading to competitive pricing strategies that can affect profitability. Innovation may best flourish through collaborative efforts focusing on precision medicine and leveraging artificial intelligence for drug discovery. Investigating the gut-brain axis could unveil new therapeutic avenues, while patient-centric research might tailor treatments more effectively. The market exhibits a high degree of competitiveness and consolidation, necessitating strategic alliances and partnerships. Overall, the market is dynamic, propelled by scientific innovation and evolving healthcare priorities, but requires overcoming substantial regulatory and economic challenges to fully realize its potential.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Inflammatory Bowel Disease Treatment Market

The Inflammatory Bowel Disease Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of inflammatory bowel disease worldwide
  • Rising awareness programs for the IBD treatment
• Market Restraints
  • High treatment costs of IBD treatment
• Market Opportunities
  • Rising research & development activities for the development of novel IBD treatment
  • Increasing approvals of novel therapeutics associated with IBD treatments
• Market Challenges
  • Regulatory hurdles and lengthy approval processes with inflammatory bowel disease treatments

Porter's Five Forces: A Strategic Tool for Navigating the Inflammatory Bowel Disease Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Inflammatory Bowel Disease Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Inflammatory Bowel Disease Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Inflammatory Bowel Disease Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Inflammatory Bowel Disease Treatment Market

A detailed market share analysis in the Inflammatory Bowel Disease Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Inflammatory Bowel Disease Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Inflammatory Bowel Disease Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Inflammatory Bowel Disease Treatment Market

A strategic analysis of the Inflammatory Bowel Disease Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Inflammatory Bowel Disease Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Abivax, Bristol-Myers Squibb Company, Cipla Limited, Eli Lilly and Company, Entera Bio Ltd., GlaxoSmithKline PLC, Ironwood Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Morphic Therapeutic, Inc., Nestle S.A., OPKO Health, Inc., Pfizer Inc., Sanofi SA, Sun Pharma Limited, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB S.A., Viatris Inc., and Zealand Pharma A/S.

Market Segmentation & Coverage

This research report categorizes the Inflammatory Bowel Disease Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Crohn's Disease and Ulcerative Colitis.
• Based on Drug Class, market is studied across Aminosalicylates, Anti-Integrin, Corticosteroids, IL Inhibitors, JAK Inhibitors, and TNF Inhibitors.
• Based on Route of Administration, market is studied across Injectable and Oral.
• Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of inflammatory bowel disease worldwide
    • 5.1.1.2. Rising awareness programs for the IBD treatment
  • 5.1.2. Restraints
    • 5.1.2.1. High treatment costs of IBD treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising research & development activities for the development of novel IBD treatment
    • 5.1.3.2. Increasing approvals of novel therapeutics associated with IBD treatments
  • 5.1.4. Challenges
    • 5.1.4.1. Regulatory hurdles and lengthy approval processes with inflammatory bowel disease treatments
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Growing usage of inflammatory bowel disease treatment to manage the rising prevalence of Crohn's diseases
  • 5.2.2. Distribution Channel: Growing accessibility of IBD drugs through online pharmacies due to their convenience
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Inflammatory Bowel Disease Treatment Market, by Type

• 6.1. Introduction
• 6.2. Crohn's Disease
• 6.3. Ulcerative Colitis

7. Inflammatory Bowel Disease Treatment Market, by Drug Class

• 7.1. Introduction
• 7.2. Aminosalicylates
• 7.3. Anti-Integrin
• 7.4. Corticosteroids
• 7.5. IL Inhibitors
• 7.6. JAK Inhibitors
• 7.7. TNF Inhibitors

8. Inflammatory Bowel Disease Treatment Market, by Route of Administration

• 8.1. Introduction
• 8.2. Injectable
• 8.3. Oral

9. Inflammatory Bowel Disease Treatment Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Hospital Pharmacy
• 9.3. Online Pharmacy
• 9.4. Retail Pharmacy

10. Americas Inflammatory Bowel Disease Treatment Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Inflammatory Bowel Disease Treatment Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Inflammatory Bowel Disease Treatment Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. FDA Approves Skyrizi for Ulcerative Colitis, Enhancing AbbVie's IBD Treatment Options
  • 13.3.2. AbbVie and FutureGen Join Forces to Develop Advanced Therapies for Inflammatory Bowel Disease
  • 13.3.3. Sanofi and Teva Join Forces to Develop New Treatment for Inflammatory Bowel Disease
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Abivax
• 3. Bristol-Myers Squibb Company
• 4. Cipla Limited
• 5. Eli Lilly and Company
• 6. Entera Bio Ltd.
• 7. GlaxoSmithKline PLC
• 8. Ironwood Pharmaceuticals, Inc.
• 9. Johnson & Johnson Services, Inc.
• 10. Merck & Co., Inc.
• 11. Morphic Therapeutic, Inc.
• 12. Nestle S.A.
• 13. OPKO Health, Inc.
• 14. Pfizer Inc.
• 15. Sanofi SA
• 16. Sun Pharma Limited
• 17. Takeda Pharmaceutical Company Limited
• 18. Teva Pharmaceutical Industries Ltd.
• 19. UCB S.A.
• 20. Viatris Inc.
• 21. Zealand Pharma A/S